Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
Leonie K de KlerkAnuj K PatelSarah DerksEirini PectasidesJérémy AugustinMohamed UdumanNihal RamanFahire G AkarcaNadine J McClearyJames M ClearyDouglas A RubinsonJeffrey W ClarkBridget FitzpatrickLauren K BraisMegan E CavanaughAmanda J RodeMelissa G JeanPatrick H LizotteMatthew J NazzaroMariano SevergniniHui ZhengCharles S FuchsPeter C EnzingerAdam J BassPublished in: Journal for immunotherapy of cancer (2022)
Pembrolizumab monotherapy was modestly effective in refractory esophageal cancer. Circulating CXCL10 at baseline appeared to be a robust predictor of response. Other T cell exhaustion markers are upregulated in PD-L1-positive patients, suggesting that immunotherapy combinations such as anti-LAG3/programmed cell death protein 1 (PD-1) or anti-IDO1/PD-1 may be of promise in refractory esophageal cancer.
Keyphrases
- phase ii study
- open label
- ejection fraction
- end stage renal disease
- newly diagnosed
- advanced non small cell lung cancer
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- big data
- radiation therapy
- combination therapy
- amino acid
- epidermal growth factor receptor
- free survival
- study protocol
- artificial intelligence